Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
447 Interim results of a phase 1 study of the novel engineered toxin body TAK-169 in patients with relapsed or refractory multiple myeloma
Compose a Response to This Article
Other responses
No responses have been published for this article.